ALK (anaplastic lymphoma kinase, CD246)-specific CARs: new immunotherapeutic agents for the treatment of pediatric solid tumors - Archive ouverte HAL Access content directly
Journal Articles Journal for Immunotherapy of Cancer Year : 2013

ALK (anaplastic lymphoma kinase, CD246)-specific CARs: new immunotherapeutic agents for the treatment of pediatric solid tumors

(1) , (1) , (1) , (2) , (1)
1
2

Abstract

The identification of unique cell-surface proteins expressed on tumor cells, yet not expressed on normal tissues, has been challenging for pediatric malignancies. The cell sur-face tyrosine kinase ALK (CD246, anaplastic lymphoma kinase) is a promising target for neuroblastoma in that it is expressed in either native, mutated, or over-expressed forms on the plasma membrane surface
Fichier principal
Vignette du fichier
2051-1426-1-S1-P27.pdf (173.83 Ko) Télécharger le fichier
Vignette du fichier
2051-1426-1-S1-P27.xml (3.92 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Format : Other

Dates and versions

inserm-00881036 , version 1 (07-11-2013)

Identifiers

Cite

Rimas Orentas, Paola Lopomo, William Babbitt, Marc Vigny, Crystal Mackall. ALK (anaplastic lymphoma kinase, CD246)-specific CARs: new immunotherapeutic agents for the treatment of pediatric solid tumors. Journal for Immunotherapy of Cancer, 2013, 1 (Suppl 1), pp.P27. ⟨10.1186/2051-1426-1-S1-P27⟩. ⟨inserm-00881036⟩
142 View
132 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More